Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center collaborate with doctors and researchers around the world to provide advanced care in more specialties and subspecialties, more expertise in every facet of care for cancer and blood disorders, and more cutting-edge treatment options.
Thanks in part to these collaborations, we’re introducing promising new drugs and opening worldwide clinical trials that break new ground across the spectrum of cancer and blood disorders.
Current Trial for SCID-X
We are currently recruiting for this multi-institutional phase I/II trial evaluating the treatment of SCID-X1 patients with retrovirus-mediated gene transfer. Patients must:
- have a definitive diagnosis of SCID-X1 in whom HLA¬matched family donors are unavailable and who are either patients >3.5 months old and lack an HLA identical (A,B,C,DR,DQ) unrelated donor OR
- be of any age with an active, therapy-resistant infection or other medical conditions that significantly increase the risk of allogeneic transplant
Read about Agustin from Argentina, who was born with SCID-X1 and was successfully cured of the disease through participation in the clinical trial.
To refer a patient, or for more information, please contact:
Colleen Dansereau, RN, MSN, CPN, Program Manager
Learn more about our other clinical trials at the English-language Dana-Farber/Boston Children’s website, or email us at email@example.com.